Bendamustine is generally well tolerated. The most common serious (grade 3 or 4) adverse events are hematologic in nature. Gastrointestinal events are also commonly observed but are usually mild ...
There is also a two-drug combination of rituximab plus a newer chemotherapy drug, bendamustine (Belrapzo, Bendeka, Treanda). Some younger people with mantle cell lymphoma will get one or more high ...
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the ...
People who are older or have underlying health issues may not tolerate such powerful chemo drugs. In this case, doctors may start with something milder, such as bendamustine (Belrapzo, Bendeka ...
That approval also included first-line use of the drug for eligible patients unsuitable for chemo-immunotherapy, typically carried out with bendamustine plus rituximab, or dexamethasone plus ...
Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European Union for adult patients with previously untreated ...
EMA committee recommends approval of AstraZeneca’s Calquence plus chemoimmunotherapy to treat adult patients with mantle cell lymphoma: Cambridge, UK Tuesday, April 1, 2025, 17: ...
[17] Bendamustine should not be used in patients with severe renal impairment (creatinine clearance of <40 mL/min), moderate hepatic impairment (aspartate transaminase or alanine transaminase ...
The U.S. Food and Drug Administration (FDA ... Concurrently, AstraZeneca's Calquence (acalabrutinib) in combination with bendamustine and rituximab was recommended for approval in the European ...
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results